ASK REDCHAT ANYTHING ABOUT PRIME MEDICINE, INC.
Prime Medicine, Inc. (NASDAQ: PRME)
Listen to this Section
$3.47
+0.3250
(
+10.35% )
2.8M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| PM359DetailsChronic granulomatous disease |
Phase 1/2 |
Market Data
|
| Open |
$3.47 |
| Previous Close |
$3.14 |
| Volume |
2.8M |
| Market Cap |
$567.14M |
| Day Range |
$3.14 - $3.61 |
| 52 Week Range |
$1.29 - $6.94 |
| Shares Outstanding |
180.62M |
| Change % |
+10.35% |
| Net Change |
▲ 0.3250 |
| Insider Ownership |
-0.04% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Year | 2022 |
| Country | United States |
| Underwriter | J.P. Morgan, Goldman Sachs, Morgan Stanley, Jefferies, more |
Insider Ownership Transactions
Total Amount Purchased:
18,118,951.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-02-20 |
Buy |
3200000.00 |
ARCH Venture Partners XII, LLC |
| 2024-02-20 |
Buy |
3200000.00 |
ARCH Venture Partners X, LLC |
| 2024-01-19 |
Sale |
-600000.00 |
Reine Allan |
| 2023-11-14 |
Sale |
-7500.00 |
Gottesdiener Keith Michael |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 10-q |
Quarterly Reports |
65 |
Nov 07, 2025 |
| 8-k |
8K-related |
14 |
Nov 07, 2025 |
| 8-k |
8K-related |
50 |
Sep 08, 2025 |
| 8-k |
8K-related |
14 |
Aug 07, 2025 |
| 10-q |
Quarterly Reports |
68 |
Aug 07, 2025 |
| 8-k |
8K-related |
13 |
Aug 05, 2025 |
| 4 |
Insider transactions |
1 |
Aug 05, 2025 |
| 4 |
Insider transactions |
3 |
Aug 05, 2025 |
| 4 |
Insider transactions |
1 |
Aug 05, 2025 |
| 4 |
Insider transactions |
1 |
Aug 05, 2025 |